Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

Christian Rolfo, Philip Mack, Giorgio V. Scagliotti, Paul Baas, Fabrice Barlesi, Trever G. Bivona, Roy S. Herbst, Tony S. Mok, Nir Peled, Robert Pirker, Luis E. Raez, Martin Reck, Jonathan Riess, Lecia V. Sequist, Frances A. Shepherd, Lynette M. Sholl, Daniel S.W. Tan, Heather A. Wakelee, Ignacio I. Wistuba, Murry W. WynesDavid P. Carbone, Fred R. Hirsch, David R Gandara

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with considerable potential to improve clinical outcomes across multiple cancer types, including NSCLC. Assays of this nature that use blood as opposed to tumor samples are frequently referred to as liquid biopsies. An increasing number of innovative platforms have been recently developed that improve not only the fidelity of the molecular analysis but also the number of tests performed on a single specimen. Circulating tumor DNA assays for detection of both EGFR sensitizing and resistance mutations have already entered clinical practice and many other molecular tests — such as detection of resistance mutations for Anaplastic Lymphoma Kinase (ALK) receptor tyrosine kinase rearrangements — are likely to do so in the near future. Due to an abundance of new evidence, an appraisal was warranted to review strengths and weaknesses, to describe what is already in clinical practice and what has yet to be implemented, and to highlight areas in need of further investigation. A multidisciplinary panel of experts in the field of thoracic oncology with interest and expertise in liquid biopsy and molecular pathology was convened by the International Association for the Study of Lung Cancer to evaluate current available evidence with the aim of producing a set of recommendations for the use of liquid biopsy for molecular analysis in guiding the clinical management of advanced NSCLC patients as well as identifying unmet needs. In summary, the panel concluded that liquid biopsy approaches have significant potential to improve patient care, and immediate implementation in the clinic is justified in a number of therapeutic settings relevant to NSCLC.

Original languageEnglish (US)
JournalJournal of Thoracic Oncology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Biopsy
Circulating Neoplastic Cells
Neoplasms
Mutation
Molecular Pathology
DNA
Protein-Tyrosine Kinases
Patient Care
Thorax
Therapeutics

Keywords

  • Biomarkers
  • cfDNA
  • ctDNA
  • Liquid biopsy
  • Molecular analysis
  • NSCLC
  • Resistance
  • Targeted therapies

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC) : A Statement Paper from the IASLC. / Rolfo, Christian; Mack, Philip; Scagliotti, Giorgio V.; Baas, Paul; Barlesi, Fabrice; Bivona, Trever G.; Herbst, Roy S.; Mok, Tony S.; Peled, Nir; Pirker, Robert; Raez, Luis E.; Reck, Martin; Riess, Jonathan; Sequist, Lecia V.; Shepherd, Frances A.; Sholl, Lynette M.; Tan, Daniel S.W.; Wakelee, Heather A.; Wistuba, Ignacio I.; Wynes, Murry W.; Carbone, David P.; Hirsch, Fred R.; Gandara, David R.

In: Journal of Thoracic Oncology, 01.01.2018.

Research output: Contribution to journalArticle

Rolfo, C, Mack, P, Scagliotti, GV, Baas, P, Barlesi, F, Bivona, TG, Herbst, RS, Mok, TS, Peled, N, Pirker, R, Raez, LE, Reck, M, Riess, J, Sequist, LV, Shepherd, FA, Sholl, LM, Tan, DSW, Wakelee, HA, Wistuba, II, Wynes, MW, Carbone, DP, Hirsch, FR & Gandara, DR 2018, 'Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC', Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2018.05.030
Rolfo, Christian ; Mack, Philip ; Scagliotti, Giorgio V. ; Baas, Paul ; Barlesi, Fabrice ; Bivona, Trever G. ; Herbst, Roy S. ; Mok, Tony S. ; Peled, Nir ; Pirker, Robert ; Raez, Luis E. ; Reck, Martin ; Riess, Jonathan ; Sequist, Lecia V. ; Shepherd, Frances A. ; Sholl, Lynette M. ; Tan, Daniel S.W. ; Wakelee, Heather A. ; Wistuba, Ignacio I. ; Wynes, Murry W. ; Carbone, David P. ; Hirsch, Fred R. ; Gandara, David R. / Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC) : A Statement Paper from the IASLC. In: Journal of Thoracic Oncology. 2018.
@article{f6876a414af5441a86b11bf48284daeb,
title = "Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC",
abstract = "The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with considerable potential to improve clinical outcomes across multiple cancer types, including NSCLC. Assays of this nature that use blood as opposed to tumor samples are frequently referred to as liquid biopsies. An increasing number of innovative platforms have been recently developed that improve not only the fidelity of the molecular analysis but also the number of tests performed on a single specimen. Circulating tumor DNA assays for detection of both EGFR sensitizing and resistance mutations have already entered clinical practice and many other molecular tests — such as detection of resistance mutations for Anaplastic Lymphoma Kinase (ALK) receptor tyrosine kinase rearrangements — are likely to do so in the near future. Due to an abundance of new evidence, an appraisal was warranted to review strengths and weaknesses, to describe what is already in clinical practice and what has yet to be implemented, and to highlight areas in need of further investigation. A multidisciplinary panel of experts in the field of thoracic oncology with interest and expertise in liquid biopsy and molecular pathology was convened by the International Association for the Study of Lung Cancer to evaluate current available evidence with the aim of producing a set of recommendations for the use of liquid biopsy for molecular analysis in guiding the clinical management of advanced NSCLC patients as well as identifying unmet needs. In summary, the panel concluded that liquid biopsy approaches have significant potential to improve patient care, and immediate implementation in the clinic is justified in a number of therapeutic settings relevant to NSCLC.",
keywords = "Biomarkers, cfDNA, ctDNA, Liquid biopsy, Molecular analysis, NSCLC, Resistance, Targeted therapies",
author = "Christian Rolfo and Philip Mack and Scagliotti, {Giorgio V.} and Paul Baas and Fabrice Barlesi and Bivona, {Trever G.} and Herbst, {Roy S.} and Mok, {Tony S.} and Nir Peled and Robert Pirker and Raez, {Luis E.} and Martin Reck and Jonathan Riess and Sequist, {Lecia V.} and Shepherd, {Frances A.} and Sholl, {Lynette M.} and Tan, {Daniel S.W.} and Wakelee, {Heather A.} and Wistuba, {Ignacio I.} and Wynes, {Murry W.} and Carbone, {David P.} and Hirsch, {Fred R.} and Gandara, {David R}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jtho.2018.05.030",
language = "English (US)",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",

}

TY - JOUR

T1 - Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC)

T2 - A Statement Paper from the IASLC

AU - Rolfo, Christian

AU - Mack, Philip

AU - Scagliotti, Giorgio V.

AU - Baas, Paul

AU - Barlesi, Fabrice

AU - Bivona, Trever G.

AU - Herbst, Roy S.

AU - Mok, Tony S.

AU - Peled, Nir

AU - Pirker, Robert

AU - Raez, Luis E.

AU - Reck, Martin

AU - Riess, Jonathan

AU - Sequist, Lecia V.

AU - Shepherd, Frances A.

AU - Sholl, Lynette M.

AU - Tan, Daniel S.W.

AU - Wakelee, Heather A.

AU - Wistuba, Ignacio I.

AU - Wynes, Murry W.

AU - Carbone, David P.

AU - Hirsch, Fred R.

AU - Gandara, David R

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with considerable potential to improve clinical outcomes across multiple cancer types, including NSCLC. Assays of this nature that use blood as opposed to tumor samples are frequently referred to as liquid biopsies. An increasing number of innovative platforms have been recently developed that improve not only the fidelity of the molecular analysis but also the number of tests performed on a single specimen. Circulating tumor DNA assays for detection of both EGFR sensitizing and resistance mutations have already entered clinical practice and many other molecular tests — such as detection of resistance mutations for Anaplastic Lymphoma Kinase (ALK) receptor tyrosine kinase rearrangements — are likely to do so in the near future. Due to an abundance of new evidence, an appraisal was warranted to review strengths and weaknesses, to describe what is already in clinical practice and what has yet to be implemented, and to highlight areas in need of further investigation. A multidisciplinary panel of experts in the field of thoracic oncology with interest and expertise in liquid biopsy and molecular pathology was convened by the International Association for the Study of Lung Cancer to evaluate current available evidence with the aim of producing a set of recommendations for the use of liquid biopsy for molecular analysis in guiding the clinical management of advanced NSCLC patients as well as identifying unmet needs. In summary, the panel concluded that liquid biopsy approaches have significant potential to improve patient care, and immediate implementation in the clinic is justified in a number of therapeutic settings relevant to NSCLC.

AB - The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with considerable potential to improve clinical outcomes across multiple cancer types, including NSCLC. Assays of this nature that use blood as opposed to tumor samples are frequently referred to as liquid biopsies. An increasing number of innovative platforms have been recently developed that improve not only the fidelity of the molecular analysis but also the number of tests performed on a single specimen. Circulating tumor DNA assays for detection of both EGFR sensitizing and resistance mutations have already entered clinical practice and many other molecular tests — such as detection of resistance mutations for Anaplastic Lymphoma Kinase (ALK) receptor tyrosine kinase rearrangements — are likely to do so in the near future. Due to an abundance of new evidence, an appraisal was warranted to review strengths and weaknesses, to describe what is already in clinical practice and what has yet to be implemented, and to highlight areas in need of further investigation. A multidisciplinary panel of experts in the field of thoracic oncology with interest and expertise in liquid biopsy and molecular pathology was convened by the International Association for the Study of Lung Cancer to evaluate current available evidence with the aim of producing a set of recommendations for the use of liquid biopsy for molecular analysis in guiding the clinical management of advanced NSCLC patients as well as identifying unmet needs. In summary, the panel concluded that liquid biopsy approaches have significant potential to improve patient care, and immediate implementation in the clinic is justified in a number of therapeutic settings relevant to NSCLC.

KW - Biomarkers

KW - cfDNA

KW - ctDNA

KW - Liquid biopsy

KW - Molecular analysis

KW - NSCLC

KW - Resistance

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=85049420071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049420071&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2018.05.030

DO - 10.1016/j.jtho.2018.05.030

M3 - Article

C2 - 29885479

AN - SCOPUS:85049420071

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

ER -